Natural Killer (NK) Cell Therapeutics Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Increase in Patient Population with Chronic Diseases
   3. Market Restraints
      1. Manufacturing Complexity
      2. Limited Clinical Evidence
   4. Market Opportunities
      1. Strategic Initiatives by Market Players
   5. Market Trends
      1. Expansion of Clinical Trials
      2. Integration of Genetic Engineering
5. MARKET SEGMENTATION
   1. By Therapeutics
      1. NK Cell Therapies
      2. NK Cell Directed Antibodies
   2. By Approaches
      1. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
      2. Bispecific Antibodies
   3. By Application
      1. Cancer
      2. Immunoproliferative Disorders
      3. Acute Infectious Diseases
      4. Gastrointestinal Diseases
      5. Others
   4. By End User
      1. Research & Academic Institutes
      2. Hospitals
      3. Specialty Clinics
   5. By Distribution Channel
      1. Hospital Pharmacies
      2. Direct Tender
      3. Others
   6. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Acepodia Inc.
      2. Affimed GmbH
      3. Bristol-Myers Squibb Company
      4. Biohaven Pharmaceuticals
      5. Cytovia Therapeutics
      6. EMERcell
      7. Fate Therapeutics
      8. Gamida Cell
      9. Glycostem
      10. Innate Pharma, Inc.
      11. iCell Gene Therapeutics
      12. INmuneBIO
      13. ImmunityBio, Inc.
      14. Multimmune GmbH
      15. Merck KGaA
      16. Phio Pharmaceuticals
      17. PersonGenBioTherapeutics
      18. Sanofi
      19. Regeneron Pharmaceuticals Inc
      20. Takeda Pharmaceutical Company Limited
   2. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Natural Killer (NK) Cell Therapeuticsmarket?

The global market of Natural Killer (NK) Cell Therapeutics is projected to reach USD 15,551.42 Mn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Natural Killer (NK) Cell Therapeuticsmarket?

The global Natural Killer (NK) Cell Therapeutics market has an estimated annual growth rate of 17.4%.

Q.3. What are the recent trends of Natural Killer (NK) Cell Therapeuticsmarket?

Expansion of clinical trials and integration of genetic engineering are someof the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Natural Killer (NK) Cell Therapeutics?

The major companies profiled in this report include Acepodia Inc., Affimed GmbH, Bristol-Myers Squibb Company, Biohaven Pharmaceuticals, Cytovia Therapeutics, EMERcell, Fate Therapeutics, Gamida Cell, Glycostem, Innate Pharma, Inc., iCell Gene Therapeutics, INmuneBIO, ImmunityBio, Inc., Multimmune GmbH, Merck KGaA, Phio Pharmaceuticals, PersonGenBioTherapeutics, Sanofi, Regeneron Pharmaceuticals Inc, Takeda Pharmaceutical Company Limited, among others.

Q.5. Which region is estimated to held highest CAGR inNatural Killer (NK) Cell Therapeuticsmarket?

North America is estimated to hold biggest share in the market for Natural Killer (NK) Cell Therapeutics.